Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

A Mitochondrial Transport Protein Protects Cancer Cells from Toxic Nanoparticles

By BiotechDaily International staff writers
Posted on 06 Jun 2013
Image: Senior author Dr. Priyabrata Mukherjee (Photo courtesy of the Mayo Clinic).
Image: Senior author Dr. Priyabrata Mukherjee (Photo courtesy of the Mayo Clinic).
A recent paper stressed the importance of linking the use of anticancer nanoparticle drugs and drug carriers to a basic understanding of the role of the mitochondria in the apoptotic process.

Cancer cells are surprisingly resistant to toxic effects of positively charged gold nanoparticles (+AuNPs). Investigators at the Mayo Clinic (Rochester, MN, USA) examined the interaction of +AuNPs with ovarian cancer cells growing in culture in order to determine the molecular mechanism protecting the cancer cells from the nanoparticles.

They reported in the April 24, 2013, online edition of the Journal of Biological Chemistry that the protein MICU1, a mitochondrial calcium uniporter, as a key molecule conferring cancer cells with resistance to +AuNPs. A uniporter is an integral membrane protein, either a channel or a carrier protein that is involved in facilitated diffusion. Uniporter carrier proteins work by binding to one molecule of solute at a time and transporting it with the solute gradient.

The MICU1 (mitochondrial calcium uptake 1) gene encodes an essential regulator of mitochondrial Ca2+ uptake under basal conditions. The encoded protein interacts with the mitochondrial calcium uniporter, a mitochondrial inner membrane Ca2+ channel, and is essential in preventing mitochondrial Ca2+ overload, which can cause excessive production of reactive oxygen species and cell stress.

The investigators found that in the ovarian cancer cells the increase in cytosolic Ca2+ induced by +AuNPs was balanced by MICU1, which prevented cell death. Silencing MICU1 decreased Bcl-2 (B-cell lymphoma 2), expression and increased caspase-3 activity and cytosolic cytochrome C levels—effects further enhanced in the presence of +AuNPs—thus initiating the mitochondrial pathway for apoptosis.

"This study identifies a novel mechanism that protects ovarian cancer cells by preventing the cell death, or apoptosis, which should occur when they encounter positively charged nanoparticles," said senior author Dr. Priyabrata Mukherjee, associate professor of biomedical engineering at the Mayo Clinic. "Furthermore, this work establishes MICU1 as a novel regulator of the apoptotic machinery in cancer cells and emphasizes the need to synergize nanoparticle design with understanding of mitochondrial machinery for enhancing targeted cellular toxicity."


Related Links:

Mayo Clinic



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.